Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease

American Journal of the Medical Sciences

Volumn 339, Issue 2, 2010, Pages 157-163

  Nakamura, Tsukasa ^a   Sato, Eiichi ^a   Fujiwara, Nobuharu ^a   Kawagoe, Yasuhiro ^a   Ueda, Yoshihiko ^b   Sugaya, Takeshi ^c   Yamagishi, Shoichi ^d   Yamada, Shingo ^e   Koide, Hikaru ^f  

^a Department of Gastroenterology and Hepatology Shinmatsudo Central General Hospital   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SHINO TEST CORPORATION   (Japan)

^f KOTO HOSPITAL   (Japan)

Author keywords

Amlodipine; Atherosclerosis; Benidipine; Chronic kidney disease; Liver type fatty acid binding protein

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMLODIPINE; BENIDIPINE; BIOLOGICAL MARKER; CREATININE; FATTY ACID BINDING PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; LIVER TYPE FATTY ACID BINDING PROTEIN; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERTENSION; MALE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 77049117063     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181c643df     Document Type: Article

References (46)

1. Peterson JC, Adler S, Burkart JM, et al. The Modification of Diet in Renal Disease Study: blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995;123:754-762
2. Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004;15:1616-1622 (Pubitemid 38679687)
3. Dogra G, Irish A, Chan D, et al. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 2006;48:926-934
4. De Leeuw PW, Thijs L, Birkenhager WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002;13: 2213-2222
5. Kamijo A, Sugaya T, Hikawa A, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005;145:125-133
6. Wang MC, Tsai WC, Chen JY, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005;45:494-501.
7. Preston E, Ellis MR, Kulinskaya E, et al. Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD. Am J Kidney Dis 2005;46:856-862
8. Ueda S, Yamagishi S, Kaida Y, et al. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology 2007;12:582-592
9. Inoue K, Kawahara K, Biswas KK, et al. HMGB1 expression by activated smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007;16:136-143
10. Porto A, Palumbo R, Pieroni M, et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box-1 protein. FASEB J 2006;20:2565-2566
11. Japanese Society of Hypertension Guidelines Committee for Renal Disease and Hypertension. Guidelines for the management of hypertension (JSH 2004), Tokyo, Japan: Life Science; 2004. p. 41-44
12. Furukawa T, Yamakawa T, Midera T, et al. Selectivities of dihydropyridine derivatives in blocking Ca2-channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999;291:464-473
13. Hayashi K, Nagahama T, Oka K, et al. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996;19:31-36
14. Morikawa T, Okumura M, Konishi Y, et al. Effects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res 2002;25:571-576
15. Abe M, Okada K, Maruyama T, et al. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009;31:270-275
16. Fukumoto Y, Yasuda S, Ito A, et al. Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlodipine. J Cardiovasc Pharmacol 2008;51:253-257
17. Matsubara M, Akizuki O, Ikeda J, et al. Benidipine, an antihypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded strokeprone spontaneously hypertensive rats. Eur J Pharmacol 2008;580:201-213
18. Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007;11:41-50. (Pubitemid 46474965)
19. Saito S, Yamauchi H, Hasui Y, et al. Quantitative determination of urinary 8-hydroxydeoxyguanosine (8-OH-dG) by using ELISA. Res Commun Mol Pathol Pharmacol 2000;107:39-44.
20. Miwa M, Matsumaru H, Akimoto Y, et al. Quantitative determination of urinary 8-hydroxy-2--deoxyguanosine level in healthy Japanese volunteers. Biofactors 2004;22:249-253
21. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004;53:1382-1386 (Pubitemid 39222104)
22. Maeda N, Sawayama Y, Tatsukawa M, et al. Chlamydia pneumoniae, seropositivity and early carotid atherosclerosis in a suburban Japanese population. Atherosclerosis 2002;164:313-319
23. Yamada S, Inoue K, Yakabe K, et al. High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 2003;49:1535-1537
24. Yamada S, Yakabe K, Ishii J, et al. New high mobility group box 1 assay system. Clin Chim Acta 2006;372:173-178
25. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006;17:2176-2183
26. de Portu S, Mantovani LG. Amlodipine: a pharmacoeconomic review. J Med Econ 2009;12:60-68
27. Kaneshiro Y, Ichihara A, Sakoda M, et al. Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 2009;32:51-58
28. Das R, Burke T, Van Wagoner DR, et al. L-type calcium channel blockers exert an anti-inflammatory effect by suppressing expression of plasminogen receptors on macrophages. Cir Res 2009;105:167-175
29. Kumagai H, Hayashi K, Kumamaru H, et al. Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens 2000;13:980-985
30. Iino Y, Hayashi M, Kawamura T, et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension-a report of the Japanese Valsartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004;27:21-30.
31. Yamashita T, Kawashima S, Ozaki M, et al. A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens 2001;19:451-458
32. Seino H, Miyaguchi S, Yamazaki T, et al. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine. Arzneimittelforschung 2007;57:526-531
33. Ohishi M, Takagi T, Ito N, et al. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res 2007;30: 797-806.
34. Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007;30:621-626
35. Suzuki O, Yoshida T, Tani S, et al. Antioxidative effects of benidipine hydrochloride in patients with hypertension independent of antihypertensive effects. Relationship between blood pressure and oxidative stress. Arzneimittelforschung 2004;54:505-512
36. Yamada S, Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007;375:36-42.
37. van Zoelen MA, Laterre PF, van Veen SQ, et al. Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 2007;35:2799-2804
38. Bruchfeld A, Qureshi AR, Lindholm B, et al. High mobility group box protein 1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008;14:109-115
39. Sato F, Maruyama S, Hayashi H, et al. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008;108:c194-201.
40. Ueda S, Yamagishi S, Matsumoto Y, et al. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007;11:115-121
41. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage 1 chronic kidney disease. Kidney Int 2006;70:781-787
42. Aslam S, Santha T, Leone A, et al. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006;70:2109-2115
43. Jepson RE, Syme HM, Vallance C, et al. Plasma asymmetric dimethylarginine, symmetric dimethylarginine, l-arginine, and nitrite/nitrate concentrations in cats with chronic kidney disease and hypertension. J Vet Intern Med 2008;22:317-324
44. Terpstra WF, May JF, Smit AJ, et al. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004;22:1309-1316
45. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006;20:787-794 (Pubitemid 44430678)
46. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003;16:439-444